ImageneBio (NASDAQ:IMA) Shares Down 1.3% - Should You Sell?

Key Points

• ImageneBio's stock fell by 1.3%, trading between $13.41 and $13.46 on a volume decrease from the average session.
• Analysts at Wedbush lowered their price target from $25.00 to $23.00 while maintaining a "neutral" rating, with overall consensus rating at "Moderate Buy."
• Recent insider trading saw Director David P. Bonita and Director Otello Stampacchia significantly increase their ownership stakes in the company with purchases at an average of $29.90 per share.

ImageneBio, Inc. (NASDAQ:IMA - Get Free Report)'s share price traded down 1.3% on Thursday . The stock traded as low as $13.41 and last traded at $13.46. 15,641 shares were traded during mid-day trading, a decline of 6% from the average session volume of 16,592 shares. The stock had previously closed at $13.64.

Wall Street Analysts Forecast Growth

Separately, Wedbush lowered their target price on ImageneBio from $25.00 to $23.00 and set a "neutral" rating on the stock in a report on Friday, July 25th. One investment analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $35.50.

ImageneBio Price Performance

The company has a 50-day moving average price of $15.32 and a 200-day moving average price of $15.23. The firm has a market capitalization of $55.15 million, a PE ratio of -1.79 and a beta of 0.49.

ImageneBio (NASDAQ:IMA - Get Free Report) last issued its quarterly earnings data on Thursday, July 24th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.14) by $0.08. On average, research analysts predict that ImageneBio, Inc. will post -0.91 earnings per share for the current fiscal year.

Insider Buying and Selling at ImageneBio

In other ImageneBio news, Director David P. Bonita bought 83,611 shares of ImageneBio stock in a transaction that occurred on Friday, July 25th. The shares were purchased at an average cost of $29.90 per share, for a total transaction of $2,499,968.90. Following the completion of the transaction, the director owned 287,885 shares of the company's stock, valued at $8,607,761.50. This represents a 40.93% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Otello Stampacchia bought 267,556 shares of ImageneBio stock in a transaction that occurred on Friday, July 25th. The shares were acquired at an average price of $29.90 per share, for a total transaction of $7,999,924.40. Following the completion of the transaction, the director directly owned 454,982 shares of the company's stock, valued at $13,603,961.80. This trade represents a 142.75% increase in their position. The disclosure for this purchase can be found here. 5.94% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On ImageneBio

Several large investors have recently added to or reduced their stakes in the business. Goldman Sachs Group Inc. lifted its position in ImageneBio by 62.4% during the first quarter. Goldman Sachs Group Inc. now owns 76,464 shares of the company's stock worth $98,000 after buying an additional 29,369 shares during the period. Aldebaran Capital LLC purchased a new position in ImageneBio during the first quarter worth about $317,000. XTX Topco Ltd lifted its position in ImageneBio by 350.6% during the first quarter. XTX Topco Ltd now owns 56,452 shares of the company's stock worth $72,000 after buying an additional 43,924 shares during the period. BML Capital Management LLC lifted its position in ImageneBio by 3.5% during the first quarter. BML Capital Management LLC now owns 3,710,803 shares of the company's stock worth $4,750,000 after buying an additional 124,937 shares during the period. Finally, Squarepoint Ops LLC purchased a new position in ImageneBio during the fourth quarter worth about $72,000. 75.00% of the stock is currently owned by hedge funds and other institutional investors.

About ImageneBio

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025.